CTLA4 and colitis: As reported by the ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up of immunotherapy toxicities [20], colitis occurs in 10% of patients who received anti-CTLA4 and in 15% of those receiving a combination,